GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zim Laboratories Ltd (BOM:541400) » Definitions » Debt-to-Revenue

Zim Laboratories (BOM:541400) Debt-to-Revenue : 0.23 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Zim Laboratories Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Zim Laboratories's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹732 Mil. Zim Laboratories's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹356 Mil. Zim Laboratories's annualized Revenue for the quarter that ended in Mar. 2024 was ₹4,715 Mil. Zim Laboratories's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 0.23.


Zim Laboratories Debt-to-Revenue Historical Data

The historical data trend for Zim Laboratories's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zim Laboratories Debt-to-Revenue Chart

Zim Laboratories Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.35 0.28 0.16 0.16 0.30

Zim Laboratories Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.15 - 0.18 - 0.23

Competitive Comparison of Zim Laboratories's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Zim Laboratories's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zim Laboratories's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zim Laboratories's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Zim Laboratories's Debt-to-Revenue falls into.



Zim Laboratories Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Zim Laboratories's Debt-to-Revenue for the fiscal year that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(732.238 + 356.006) / 3674.244
=0.30

Zim Laboratories's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(732.238 + 356.006) / 4714.512
=0.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


Zim Laboratories Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Zim Laboratories's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Zim Laboratories (BOM:541400) Business Description

Traded in Other Exchanges
Address
Nelson Square, Chhindwara Road, Sadoday Gyan, Ground Floor, Opposite NADT, Nagpur, MH, IND, 440 013
Zim Laboratories Ltd is a pharmaceutical company. It is mainly engaged in the manufacturing of formulation drugs and pre-formulation ingredients. Geographically, the group has a business presence in India and other countries, of which key revenue is derived from Outside India. The products offered by the company are Ondansetron, Tadalafil, Vitamin D3, Levocetirizine, Methylcobalamin, and others. The majority of its revenue gets derived from the sale of pharmaceutical goods.

Zim Laboratories (BOM:541400) Headlines

No Headlines